VFA
KPTI icon

Valeo Financial Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Valeo Financial Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-140
Closed -$22K – 1206
2021
Q1 		$22K Buy
+140
New +$29.5K ﹤0.01% 1138
2020
Q4 		– Hold
0
– – – 1759
2020
Q3 		– Hold
0
– – – 1883
2020
Q2 		– Hold
0
– – – 2092
2020
Q1 		– Hold
0
– – – 1855
2019
Q4 		– Hold
0
– – – 1670
2019
Q3 		– Hold
0
– – – 1624
2019
Q2 		– Hold
0
– – – 1612
2019
Q1 		– Hold
0
– – – 1597
2018
Q4 		– Hold
0
– – – 1611
2018
Q3 		– Hold
0
– – – 1820
2018
Q2 		– Hold
0
– – – 1691
2018
Q1 		– Hold
0
– – – 1578

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Valeo Financial Advisors's KPTI Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 140 shares — an estimated $22K sold.

Valeo Financial Advisors first reported a position in KPTI in Q1 2021 and held it in 1 quarter. The position peaked at $22K in Q1 2021. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 140 Karyopharm Therapeutics shares in Q2 2021, an estimated $22K.
  • Valeo Financial Advisors first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 1 quarter.
  • Valeo Financial Advisors's Karyopharm Therapeutics position peaked at $22K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.